Form 8-K - Current report:
SEC Accession No. 0001104659-21-105666
Filing Date
2021-08-16
Accepted
2021-08-16 08:05:00
Documents
14
Period of Report
2021-08-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2124543d2_8k.htm   iXBRL 8-K 25963
2 EXHIBIT 99-1 tm2124543d2_ex99-1.htm EX-99.1 72507
6 GRAPHIC tm2116372d2_ex4-14image01.jpg GRAPHIC 2763
  Complete submission text file 0001104659-21-105666.txt   286829

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avte-20210816.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avte-20210816_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avte-20210816_pre.xml EX-101.PRE 22362
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2124543d2_8k_htm.xml XML 3721
Mailing Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116
Business Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 211174619
SIC: 2834 Pharmaceutical Preparations